Sofinnova Partners, a Paris-based Venture Capital firm, co-leads Auris Medical Series C financing round which raised a total amount of CHF47.1M ( €368.6M)

Based in Basel (Switzerland), Auris Medical is specialised in the development of novel therapeutics for the treatment of inner ear disorders. The funds raised will contribute to finance phase III clinical development and commercialisation of its two lead compounds: AM-101 for the treatment of acute tinnitus and AM-111 for the treatment of acute inner ear hearing loss.
Antoine Papiernik, Managing Partner at Sofinnova Partners, says: “We are thrilled to back such a talented entrepreneur as Thomas Meyer. Sofinnova Partners  has followed Auris Medical’s developments since its inception in 2003, and we are pleased to bring our expertise and network to support the company’s growth at this important time in its life. Inner ear disorders are in constant growth throughout the world, when no innovative therapy has been offered for a long time on the market. Auris Medical is one of the most advanced player in this field and its products could truly answer those important medical needs.”